| scholarly article | Q13442814 |
| P50 | author | Zhao-Qian Liu | Q69033386 |
| P2093 | author name string | Wei Zhang | |
| Xiao-Ping Chen | |||
| Fa-Zhong He | |||
| Hong-Hao Zhou | |||
| Jian-Quan Luo | |||
| Yong-Fang Hu | |||
| Hai-Yan He | |||
| Ying-Zi Ming | |||
| Zhi-Ying Luo | |||
| Yue-Li Zhang | |||
| Mou-Ze Liu | |||
| Hua-Wen Xin | |||
| Ming-Jie Shao | |||
| P2860 | cites work | Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period | Q83496835 |
| [Regulatory effects of cyclosporin A and tacrolimus on the immunological gene expressions in renal transplant recipients] | Q85835574 | ||
| Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients | Q86209006 | ||
| Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination in Chinese liver transplant patients during the early post-transplantation period: results from two cohort studies | Q86823572 | ||
| Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation | Q87859988 | ||
| Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use | Q28087131 | ||
| Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients | Q28538933 | ||
| The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients | Q33628473 | ||
| PharmGKB summary: cyclosporine and tacrolimus pathways | Q33989902 | ||
| Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients | Q34065305 | ||
| The tacrolimus metabolism rate influences renal function after kidney transplantation | Q34395610 | ||
| CTLA4 gene polymorphisms influence the incidence of infection after renal transplantation in Chinese recipients | Q34981269 | ||
| Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis | Q35650886 | ||
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. | Q35782898 | ||
| A molecular perspective of CTLA-4 function | Q36427322 | ||
| Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation | Q37620393 | ||
| Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. | Q37678060 | ||
| Tacrolimus in transplant rejection | Q38066267 | ||
| Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs | Q38120290 | ||
| The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. | Q38163945 | ||
| Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. | Q38247190 | ||
| Association between interleukin-3 gene polymorphism and acute rejection after kidney transplantation | Q38478746 | ||
| A new immunosuppressant: tacrolimus | Q38645736 | ||
| Association of the CTLA4 promoter region (-1661G allele) with type 1 diabetes in the South Moroccan population | Q38917501 | ||
| Clinical pharmacokinetics of tacrolimus | Q41096852 | ||
| Using Genetic and Clinical Factors to Predict Tacrolimus Dose in Renal Transplant Recipients | Q42837771 | ||
| Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis | Q43502168 | ||
| Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. | Q43977791 | ||
| Association of CTLA-4 gene polymorphism with end-stage renal disease and renal allograft outcome | Q44542562 | ||
| CYP3A5*3 and POR*28 genetic variants influence the required dose of tacrolimus in heart transplant recipients | Q45191088 | ||
| Association between cytotoxic T lymphocyte antigen-4 +49A/G, -1722T/C, and -1661A/G polymorphisms and cancer risk: a meta-analysis | Q45395844 | ||
| Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. | Q45749580 | ||
| Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients | Q46874563 | ||
| Genetic association of interleukin-2, interleukin-4, interleukin-6, transforming growth factor-β, tumour necrosis factor-α and blood concentrations of calcineurin inhibitors in Turkish renal transplant patients | Q47729633 | ||
| The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. | Q47803890 | ||
| A functional polymorphism in the CYP3A4 gene is associated with increased risk of coronary heart disease in the Chinese Han population. | Q51521191 | ||
| The influence of CTLA-4 single nucleotide polymorphisms on acute kidney allograft rejection in Turkish patients | Q56895945 | ||
| Influence of cytotoxic T-lymphocyte antigen-4 polymorphisms on acute rejection onset of cadaveric renal transplants | Q56897395 | ||
| Polymorphisms in cytotoxic T lymphocyte associated antigen-4 influence the rate of acute rejection after renal transplantation in 167 Chinese recipients | Q56898105 | ||
| CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients | Q57550228 | ||
| In vivo effects of interleukin-10 on human cytochrome P450 activity | Q73433722 | ||
| Tacrolimus dosing in Chinese renal transplant recipients: a population-based pharmacogenetics study | Q83435750 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 415-423 | |
| P577 | publication date | 2017-01-23 | |
| P1433 | published in | Acta Pharmacologica Sinica | Q15749885 |
| P1476 | title | IL-3 and CTLA4 gene polymorphisms may influence the tacrolimus dose requirement in Chinese kidney transplant recipients | |
| P478 | volume | 38 |
| Q47741403 | Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients |
| Q57465404 | Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on tacrolimus pharmacokinetics in renal transplant recipients |
| Q47554956 | Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation. |
| Q91768250 | Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C |
| Q90955751 | Strategies to achieve immune tolerance in allogeneic solid organ transplantation |
| Q60935379 | Whole exome sequencing for the identification of CYP3A7 variants associated with tacrolimus concentrations in kidney transplant patients |
Search more.